This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Should You Buy Ramaco Resources (METC) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
METCPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
What's in Store for Bristol-Myers (BMY) in Q3 Earnings?
by Zacks Equity Research
Investors are likely to focus on Opdivo's demand along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q3 results.
AZNNegative Net Change BIIBNegative Net Change BMYNegative Net Change MRTXPositive Net Change
biotechnology earnings pharmaceuticals
Eton Pharma (ETON) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Eton Pharma's (ETON) revenues in the third quarter of 2023 are expected to have been driven by the sales of its marketed products.
ACADNegative Net Change ASNDNegative Net Change ETONNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Top Stock Reports for Apple, Amgen & Becton, Dickinson
by Sheraz Mian
Today's Research Daily features new research reports on 12 major stocks, including Apple Inc. (AAPL), Amgen Inc. (AMGN) and Becton, Dickinson and Company (BDX).
AAPLNegative Net Change UNHNegative Net Change AMGNNegative Net Change BDXNegative Net Change MPLXNegative Net Change VRSKNegative Net Change
biotechnology computers medical
Bristol Myers' (BMY) Opdivo SC Meets Kidney Cancer Study Goals
by Zacks Equity Research
Bristol Myers' (BMY) subcutaneous formulation of Opdivo, developed using Halozyme's Enhanze technology, meets noninferiority goals in a late-stage kidney cancer study compared with intravenous Opdivo.
BMYNegative Net Change HALOPositive Net Change ACETNegative Net Change ANIXNegative Net Change
biotechnology biotechs immuno-therapy medical pharmaceuticals
Ardelyx (ARDX) Up on FDA Nod to Xphozah for Hyperphosphatemia
by Zacks Equity Research
Ardelyx (ARDX) gets FDA approval for Xphozah to reduce serum phosphorus in adult patients with kidney disease on dialysis as an add-on therapy. The stock of the company climbs 13%.
DVAXNegative Net Change ACETNegative Net Change ARDXNegative Net Change ANIXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Inovio Pharma (INO) Stock Surges 19% This Month: Here's Why
by Zacks Equity Research
Inovio Pharma (INO) rises 19% this month after the FDA issues positive feedback on data from a phase I/II study on a rare respiratory disease candidate, INO-3107, which can be used to file a BLA.
DVAXNegative Net Change ACETNegative Net Change INONegative Net Change ANIXNegative Net Change
biotechnology biotechs dna-sequencing medical pharmaceuticals
Nkarta (NKTX) Rallies 112% as FDA Clears IND for Lupus Drug
by Zacks Equity Research
Nkarta (NKTX) rallies 112% on FDA nod to begin the clinical development of its investigational candidate, NKX019, for the treatment of lupus nephritis.
DVAXNegative Net Change ACETNegative Net Change ANIXNegative Net Change NKTXNegative Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
Biomea (BMEA) Doses First Patient in Leukemia Study, Stock Up
by Zacks Equity Research
Biomea (BMEA) successfully doses the first patient in its phase I study of BMF-500 to treat adult patients with acute leukemia. The company's stock rises 6.7% on the news.
DVAXNegative Net Change ACETNegative Net Change ANIXNegative Net Change BMEANegative Net Change
biotechnology biotechs medical pharmaceuticals
Kimbell Royalty (KRP) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
KRPNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More
by Ekta Bagri
Regulatory and pipeline updates from Aldeyra Therapeutics (ALDX) and Scholar Rock (SRRK) are in focus in the biotech sector.
ALDXNegative Net Change AMLXNegative Net Change EVLONo Net Change SRRKNegative Net Change ANVSNegative Net Change
biotechnology biotechs pharmaceuticals
Aldeyra (ALDX) Plummets on Dry Eye Disease Drug's Setback
by Zacks Equity Research
Aldeyra's (ALDX) new drug application for dry eye disease unlikely to be approved by the FDA due to its lack of efficacy.
NVSNegative Net Change ACADNegative Net Change ALDXNegative Net Change BLCONegative Net Change
biotechnology pharmaceuticals
Novo Nordisk (NVO) Raises Sales Outlook for 2023, Shares Gain
by Zacks Equity Research
Novo Nordisk (NVO) increases its annual sales and operating profit forecast for the second time in 2023, driven by Ozempic (semaglutide) and Wegovy.
DVAXNegative Net Change NVONegative Net Change LLYNegative Net Change ACADNegative Net Change
biotechnology pharmaceuticals
Scholar Rock (SRRK) Up on Pipeline Advancement, Stock Offering
by Zacks Equity Research
Scholar Rock (SRRK) rises on plans to advance SRK-439 for treating obesity and offering common stock.
DVAXNegative Net Change SRPTNegative Net Change ACADNegative Net Change SRRKNegative Net Change
biotechnology biotechs pharmaceuticals
Incyte (INCY) Stock Plummets 29.6% Year to Date: Here's Why
by Zacks Equity Research
Incyte (INCY) loses 29.6% year-to-date as competition increases for Jakafi and the company suffers pipeline setbacks.
GSKNegative Net Change NVSNegative Net Change INCYNegative Net Change
biotechnology biotechs
Annovis (ANVS) AD Study to Continue as Planned, Shares Rise
by Zacks Equity Research
Annovis (ANVS) gains on the release of interim independent analysis, indicating that the ongoing phase II/III study in Alzheimer's Disease is sufficiently powered to continue as planned without any additional patients.
BIIBNegative Net Change PRTANegative Net Change ANVSNegative Net Change
biotechnology biotechs
AbbVie's (ABBV) Rinvoq Meets Key Goal in Phase II Vitiligo Study
by Zacks Equity Research
AbbVie (ABBV) meets the primary goal in the phase II study evaluating Rinvoq in the treatment of adult patients with non-segmental vitiligo.
DVAXNegative Net Change INCYNegative Net Change ABBVNegative Net Change CORTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Incyte (INCY) Posts Upbeat Data From Phase II Vitiligo Study
by Zacks Equity Research
Incyte (INCY) announces new positive 52-week data from its mid-stage study of povorcitinib for the treatment of adult patients with extensive nonsegmental vitiligo.
DVAXNegative Net Change INCYNegative Net Change CORTNegative Net Change ANVSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Tempest (TPST) Up as First-Line Liver Cancer Study Meets Goals
by Zacks Equity Research
Tempest (TPST) skyrockets 2879% on positive new and updated findings from its early-mid-stage study evaluating TPST-1120 in combination with standard-of-care therapies to treat liver cancer.
RHHBYNegative Net Change DVAXNegative Net Change CORTNegative Net Change TPSTPositive Net Change
biotechnology biotechs immuno-therapy medical oncology-screening pharmaceuticals
Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces Setback
by Ekta Bagri
Acquisition and pipeline updates from Bristol Myers (BMY) and Akero Therapeutics (AKRO) are in focus in the biotech sector.
ALNYNegative Net Change BMYNegative Net Change QURENegative Net Change MRTXPositive Net Change AKRONegative Net Change
biotechnology biotechs
Novo Nordisk (NVO) Up on Positive Kidney Outcomes Study Update
by Zacks Equity Research
Novo Nordisk (NVO) is set to stop its kidney outcomes study on Ozempic based on interim analysis results that met certain pre-specified efficacy criteria for early closure. The stock rises 5.2%.
DVAXNegative Net Change NVONegative Net Change CORTNegative Net Change ANVSNegative Net Change
biotechnology biotechs medical medical-devices pharmaceuticals
The Zacks Analyst Blog Highlights Bristol Myers Squibb, Mirati Therapeutics, Eli Lilly, POINT Biopharma and Pfizer
by Zacks Equity Research
Bristol Myers Squibb, Mirati Therapeutics, Eli Lilly, POINT Biopharma and Pfizer are part of the Zacks top Analyst Blog.
BMYNegative Net Change PFENegative Net Change LLYNegative Net Change MRTXPositive Net Change
biotechnology pharmaceuticals
Nurix (NRIX) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
On Nurix's (NRIX) Q3 earnings call, investors will likely focus on updates related to its pipeline candidates for hematologic malignancies and solid tumor indications.
GILDNegative Net Change SGENPositive Net Change APLSNegative Net Change NRIXNegative Net Change
biotechnology medical
Agilent (A) Bolsters NTD Research With SIDC Partnership
by Zacks Equity Research
Agilent (A) collaborates with Sarawak Infectious Disease Centre to provide the latter with its 6475 triple quadrupole LC/MS system, enabling rapid outbreak response for neglected tropical diseases.
ANegative Net Change AMATNegative Net Change ASURNegative Net Change ANETNegative Net Change
biotechnology medical-devices tech-stocks
Alnylam (ALNY) Receives CRL for the Label Expansion of Onpattro
by Zacks Equity Research
Alnylam's (ALNY) label expansion-seeking application for Onpattro, to treat transthyretin-mediated amyloidosis with cardiomyopathy, gets the FDA's CRL on the grounds of insufficient data. The stock falls 5%.
ALNYNegative Net Change CORTNegative Net Change ANVSNegative Net Change BTTXNo Net Change
biotechnology biotechs medical pharmaceuticals